Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
August 16 2021 - 4:15PM
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
(“Brooklyn”), a biopharmaceutical company focused on exploring the
role that cytokine and gene editing/cell therapy can have in
treating patients with cancer, blood disorders, and monogenic
diseases, today announced that it will host a shareholder update
conference call on Thursday, August 19, 2021, at 4:30 p.m. ET.
Participants are asked to pre-register for the call through the
following link: https://dpregister.com/sreg/10159634/ec70e32616.
Please note that registered participants will receive their dial in
number upon registration and will dial directly into the call
without delay.
Those who do not register can access the call at 1-866-777-2509
(U.S. toll free) or 1-412-317-5413 (international). Please ask the
operator to be connected to the Brooklyn ImmunoTherapeutics call.
The conference call will also be available through a live webcast
accessible at
investor.brooklynitx.com/events-and-presentations/.
In addition to conducting a live Q&A session during the
call, Brooklyn will, to the extent time permits, address
appropriate questions that are submitted at
investors@brooklyntx.com by 5:00 p.m. ET on August 17, 2021.
Interested investors should use the subject line “BTX Call
Questions” in pre-submitting their questions.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that
cytokine, gene editing, and cell therapy can have in treating
patients with cancer, blood disorders, and monogenic diseases.
Brooklyn’s most advanced program is IRX-2, a
human cell-derived cytokine therapy, studying the safety and
efficacy of IRX-2 in patients with head and neck cancer in Phase
2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2
demonstrated an overall survival benefit. Additional studies are
either underway or planned in other solid tumor cancer
indications.
Brooklyn has multiple next-generation cell and
gene-editing therapies in preclinical development for various
indications including acute respiratory distress syndrome, solid
tumor indications, as well as in vivo gene-editing therapies for
rare genetic diseases. For more information about Brooklyn and its
clinical programs, please visit www.BrooklynITx.com.
Investor Relations Contact:CORE
IR516-222-2560investors@brooklynitx.com
Media Contact:CORE IRJules
Abraham917-885-7378julesa@coreir.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024